1. Home
  2. GRFS vs ALKS Comparison

GRFS vs ALKS Comparison

Compare GRFS & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Grifols S.A.

GRFS

Grifols S.A.

HOLD

Current Price

$8.71

Market Cap

6.5B

Sector

Health Care

ML Signal

HOLD

Logo Alkermes plc

ALKS

Alkermes plc

HOLD

Current Price

$29.34

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRFS
ALKS
Founded
1940
1987
Country
Spain
Ireland
Employees
23800
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5B
5.5B
IPO Year
N/A
2012

Fundamental Metrics

Financial Performance
Metric
GRFS
ALKS
Price
$8.71
$29.34
Analyst Decision
Hold
Buy
Analyst Count
2
14
Target Price
$10.15
$43.43
AVG Volume (30 Days)
608.0K
1.7M
Earning Date
01-01-0001
05-22-2026
Dividend Yield
1.65%
N/A
EPS Growth
N/A
N/A
EPS
N/A
1.43
Revenue
N/A
$1,475,899,000.00
Revenue This Year
$5.33
$24.06
Revenue Next Year
$6.50
$4.53
P/E Ratio
$18.67
$20.30
Revenue Growth
N/A
N/A
52 Week Low
$6.19
$25.17
52 Week High
$11.14
$36.32

Technical Indicators

Market Signals
Indicator
GRFS
ALKS
Relative Strength Index (RSI) 39.04 34.39
Support Level $8.66 $29.20
Resistance Level $9.11 $31.69
Average True Range (ATR) 0.27 1.13
MACD -0.08 -0.53
Stochastic Oscillator 27.18 8.69

Price Performance

Historical Comparison
GRFS
ALKS

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

About ALKS Alkermes plc

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

Share on Social Networks: